Section Arrow
KURA.NASDAQ
- Kura Oncology
Quotes are at least 15-min delayed:2024/12/24 12:55 EST
Last
 8.89
-0.05 (-0.56%)
Day High 
9.015 
Prev. Close
8.94 
1-M High
11.62 
Volume 
587.02K 
Bid
8.89
Ask
8.9
Day Low
8.75 
Open
8.91 
1-M Low
8.76 
Market Cap 
695.21M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 9.56 
20-SMA 10.24 
50-SMA 14.24 
52-W High 24.17 
52-W Low 8.76 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.35/-2.29
Enterprise Value
710.90M
Balance Sheet
Book Value Per Share
5.45
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.383529-0.019571-4.86%-- 
CMNDClearmind Medicine1.695+0.475+38.93%0.16PE
CEROCERo Therapeutics Holdings0.0603+0.0098+19.41%-- 
RXRXRecursion Pharmaceuticals7.2831+0.2931+4.19%-- 
CDTConduit Pharmaceuticals0.057699+0.003199+5.87%-- 
Quotes are at least 15-min delayed:2024/12/24 12:55 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operationof the group is carried through the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.